EUCTR2007-001116-22-LT进行中（未招募）不适用
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 602
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patient has histologically or cytologically confirmed colorectal cancer.
- •2.Patient has at least one measurable lesion greater than or equal to 20 mm.
- •3.Patient has previously failed both irinotecan and oxaliplatin containing regimens and should have progressed on or within 3 months of completing their last line of therapy with objective radiological evidence of progression.
- •4.Patient is male or female, and =18 years of age on the day of signing informed consent.
- •5.Patient has performance status 0-1 on the ECOG Performance Scale.
- •6.Patient has adequate organ function as indicated by the following laboratory values:
- •Absolute Neutrophil Count (ANC) =1,500/mcL
- •Platelets =100,000/mcL
- •Hemoglobin =9 g/dL-without qualifications, use of erythropoietin and transfusions are allowed
- •Serum Creatinine/calculated creatine clearance =2 times the upper limit of normal (ULN)/ =60 mL/min (patients with creatinine levels =2 times the ULN). Patient may not be on dialysis. (Creatinine clearance should be calculated per institutional standard.)
- •Serum total bilirubin=1.5 times the ULN
- •AST (SGOT) and ALT (SGPT) =5 times the ULN
- •Prothrombin time (PT) =1.2 times the ULN
- •Partial Thromboplastin time (PTT) =1.2 times the ULN
- •7. Patient has archival tumor available for analysis for biomarker studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
- •1.Patient has histologically or cytologically confirmed colorectal cancer.
- •2.Patient has at least one measurable lesion greater than or equal to 20 mm.
- •3.Patient has previously failed both irinotecan and oxaliplatin containing regimens and should have progressed on or within 3 months of completing their last line of therapy with objective radiological evidence of progression.
- •4.Patient is male or female, and =18 years of age on the day of signing informed consent.
- •5.Patient has performance status 0-1 on the ECOG Performance Scale.
- •6.Patient has adequate organ function as indicated by the following laboratory values:
- •Absolute Neutrophil Count (ANC) =1,500/mcL
- •Platelets =100,000/mcL
- •Hemoglobin =9 g/dL-without qualifications, use of erythropoietin and transfusions are allowed
- •Serum Creatinine/calculated creatine clearance =2 times the upper limit of normal (ULN)/ =60 mL/min (patients with creatinine levels =2 times the ULN). Patient may not be on dialysis. (Creatinine clearance should be calculated per institutional standard.)
- •Serum total bilirubin=1.5 times the ULN
- •AST (SGOT) and ALT (SGPT) =5 times the ULN
- •Prothrombin time (PT) =1.2 times the ULN
- •Partial Thromboplastin time (PTT) =1.2 times the ULN
- •7. Patient has archival tumor available for analysis for biomarker studies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to initial dosing on this study or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline.
- •2.Patient is currently participating or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the investigational agent, whichever is longer, of initial dosing on this study.
- •3.Patient has experienced intolerable toxicity to irinotecan therapy.
- •4.Patient has prior exposure to IGF-1R inhibitors or EGFR inhibitors (e.g. cetuximab).
- •5.Patient has CNS metastases and/or carcinomatous meningitis.
- •6.Patient has primary central nervous system tumor.
- •7.Patient has a known hypersensitivity to the components of study drugs or its analogs that is not treatable by premedication with antihistamines and steroids.
- •8.Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- •9.Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk for recurrence by his/her treating physician.
- •10.Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study.
- •11.Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
- •12.Patient has known active Hepatitis B or C.
- •13.Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
- •14.Patient is concurrently using growth hormone (GH), or growth hormone inhibitors.
- •1.Patient who has had chemotherapy, radiotherapy, or biological therapy within 2 weeks prior to initial dosing on this study or whose toxicities from agents administered 2 weeks earlier have not resolved to at least grade 1 or baseline.
- •2.Patient is currently participating or has participated in a study with an investigational compound or device within 30 days or 5 half-lives of the investigational agent, whichever is longer, of initial dosing on this study.
- •3.Patient has experienced intolerable toxicity to irinotecan therapy.
- •4.Patient has prior exposure to IGF-1R inhibitors or EGFR inhibitors (e.g. cetuximab).
- •5.Patient has CNS metastases and/or carcinomatous meningitis.
- •6.Patient has primary central nervous system tumor.
- •7.Patient has a known hypersensitivity to the components of study drugs or its analogs that is not treatable by premedication with antihistamines and steroids.
- •8.Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- •9.Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; who has undergone potentially curative therapy with no evidence of that disease for five years, or who is deemed at low risk for recurrence by his/her treating physician.
- •10.Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study.
- •11.Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
- •12.Patient has known active Hepatitis B or C.
- •13.Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
- •14.Patient is concurrently using growth hormone (GH), or growth hormone inhibitors.
研究者
相似试验
进行中（未招募）
1 期
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal CancerEUCTR2007-001116-22-DKMerck & Co., Inc.1,168
进行中（未招募）
不适用
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancermetastatic colorectal carcinomaMedDRA version: 9.1Level: LLTClassification code 10010036Term: Colorectal carcinomaMedDRA version: 9.1Level: LLTClassification code 10027477Term: Metastatic carcinomaEUCTR2007-001116-22-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,168
进行中（未招募）
不适用
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal CancerEstudio en fase II/III del tratamiento con MK-0646 combinado con cetuximab e irinotecán en pacientes con cáncer colorrectal metastásicometastatic colorectal carcinomacarcinoma colorrectal metastásicoMedDRA version: 9.1Level: LLTClassification code 10010036Term: Colorectal carcinomaMedDRA version: 9.1Level: LLTClassification code 10027477Term: Metastatic carcinomaEUCTR2007-001116-22-ESMerck Sharp & Dohme de España, S.A.1,100
进行中（未招募）
不适用
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal CancerEUCTR2007-001116-22-SEMerck Sharp & Dohme (Sweden) AB1,100
进行中（未招募）
1 期
A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancermetastatic colorectal carcinomaMedDRA version: 9.1 Level: LLT Classification code 10010036 Term: Colorectal carcinomaMedDRA version: 9.1 Level: LLT Classification code 10027477 Term: Metastatic carcinomaEUCTR2007-001116-22-FIMSD Finland Oy1,100